SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[_] Definitive Proxy Statement
[X] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-12
ICN Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Registrant as Specified in its Charter)
N/A
--------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
Following is the text of a press release issued by ICN Pharmaceuticals,
Inc. on May 6, 2002:
Media: Investors:
----- ---------
Alan Charles Joe Schepers
714-545-0100 ext. 3013 212-754-4422
ICN PHARMACEUTICALS ANNOUNCES LAUNCH OF PROXY WEBSITE
Costa Mesa, Calif., May 6, 2002 -- ICN Pharmaceuticals, Inc. (NYSE: ICN)
announced today the launch of its Proxy Website in order to permit
stockholders of ICN and other interested parties to obtain access to
materials relevant to ICN's upcoming annual meeting and to facilitate
stockholder communication with ICN.
The Proxy Website can be accessed through ICN's website at www.icnpharm.com
by clicking on the hyperlink labeled "Learn more about ICN's Annual
Meeting" on the left side of the homepage. In addition, the Proxy Website
can be accessed at www.icnproxy.com and www.icnannualmeeting.com.
A synopsis of ICN's proven successful track record is provided in the link
entitled "Why Support ICN's management". Brief background information
provided in the "Take a Look at the ICN Board Slate" link highlights the
accomplished ICN recommended nominees and their qualifications. The third
link, "How ICN Increases Shareholder Value", illustrates ICN's on-going
commitment to unlocking maximum shareholder value through optimal
valuation.
ICN, headquartered in Costa Mesa, California, is an innovative
research-based company. Its therapeutic focus is in anti-infectives,
including anti-virals, dermatology and oncology. Ribavirin, Levovirin(TM)
and Viramidine(TM) were discovered in ICN laboratories.
Additional information is also available on the Company's website at
http://www.icnpharm.com.
THE 'SAFE HARBOR' STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995. This press release contains forward-looking statements that
involve risks and uncertainties, including but not limited to, the
company's ability to complete its restructuring plan according to stated
timeframes, projections for future sales, operating income, returns on
invested assets, regulatory approval processes, and other risks detailed
from time to time in the Company's Securities and Exchange Commission
filings.